Literature DB >> 16061717

Protein C in pneumonia.

G Choi, M J Schultz, M Levi, T van der Poll, J L Millo, C S Garrard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16061717      PMCID： PMC1747500          DOI： 10.1136/thx.2004.037341

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  11 in total

1.  Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation.

Authors:  Rogier M Determann; Julian L Millo; Chris S Garrard; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2006-04-14       Impact factor: 17.440

2.  Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury.

Authors:  Marcus J Schultz; Marcel Levi
Journal:  Thorax       Date:  2007-07       Impact factor: 9.139

Review 3.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

4.  Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients.

Authors:  Mitchell Jay Cohen; Mariah Call; Mary Nelson; Carolyn S Calfee; Charles T Esmon; Karim Brohi; Jean Francois Pittet
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

5.  Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study.

Authors:  Marcel Schouten; Koenraad F van der Sluijs; Bruce Gerlitz; Brian W Grinnell; Joris J T H Roelofs; Marcel M Levi; Cornelis van 't Veer; Tom van der Poll
Journal:  Crit Care       Date:  2010-04-14       Impact factor: 9.097

6.  Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study.

Authors:  Marcel Schouten; Cornelis van't Veer; Joris J T H Roelofs; Marcel Levi; Tom van der Poll
Journal:  Crit Care       Date:  2010-08-03       Impact factor: 9.097

Review 7.  Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies.

Authors:  Jenny Juschten; Pieter R Tuinman; Nicole P Juffermans; Barry Dixon; Marcel Levi; Marcus J Schultz
Journal:  Ann Transl Med       Date:  2017-11

8.  Tissue plasminogen activator attenuates ventilator-induced lung injury in rats.

Authors:  Liang-ti Huang; Hsiu-chu Chou; Leng-fang Wang; Chung-ming Chen
Journal:  Acta Pharmacol Sin       Date:  2012-07-16       Impact factor: 6.150

9.  Early intravenous unfractionated heparin and outcome in acute lung injury and acute respiratory distress syndrome: a retrospective propensity matched cohort study.

Authors:  Jorrit J Hofstra; Alexander P J Vlaar; David J Prins; Gavin Koh; Marcel Levi; Marcus J Schultz; Jan M Binnekade; Nicole P Juffermans
Journal:  BMC Pulm Med       Date:  2012-08-15       Impact factor: 3.317

10.  Relative Tissue Factor Deficiency Attenuates Ventilator-Induced Coagulopathy but Does Not Protect against Ventilator-Induced Lung Injury in Mice.

Authors:  Esther K Wolthuis; Alexander P J Vlaar; Goda Choi; Joris J T H Roelofs; Marcel Levi; Nicole P Juffermans; Marcus J Schultz
Journal:  Crit Care Res Pract       Date:  2011-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.